08:39 AM EDT, 06/24/2025 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Tuesday that it has entered a partnership with Perceptive Xontogeny Venture Funds (PXV Funds) and venBio Partners to advance RNA-based therapies for genetic cardiac diseases.

The partnership includes an investment of up to $40 million from PXV Funds and venBio Partners to seed a new entity focused on advancing research for novel RNA-based therapeutics. Lexeo will contribute preclinical intellectual property and its expertise in developing cardiac genetic medicines as part of the deal.

Lexeo has received a double-digit percentage equity position in the new entity. The company will also be entitled to future milestone payments, royalties, and opt-in rights to certain programs.

The funding is non-dilutive to existing Lexeo shareholders.